Insulet Corporation Deferred Revenue 2011-2026 | PODD

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Insulet Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
14 M	12 M	15.4 M	16.1 M	3.5 M	5.4 M	3.2 M	1.2 M	2.36 M	1.31 M	2.36 M	1.55 M	900 K	5.44 M	2.58 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
16.1 M	900 K	5.82 M

Quarterly Deferred Revenue Insulet Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
16.5 M	17.4 M	15.4 M	12 M	22.8 M	21.9 M	18.2 M	15.4 M	13.8 M	19.4 M	22.2 M	16.1 M	9 M	6.3 M	3.8 M	3.5 M	3.5 M	3.2 M	3.5 M	5.4 M	4.3 M	5 M	3.8 M	3.2 M	3.2 M	3.2 M	3.2 M	1.2 M	1.18 M	1.18 M	2.81 M	2.36 M	1.4 M	1.13 M	1.13 M	1.31 M	1.31 M	1.31 M	1.31 M	2.36 M	2.36 M	2.36 M	2.36 M	1.55 M	1.55 M	1.55 M	1.55 M	900 K	900 K	900 K	900 K	5.44 M	5.44 M	5.44 M	5.44 M	2.58 M	2.58 M	2.58 M	2.58 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
22.8 M	900 K	5.83 M

Deferred Revenue of other stocks in the Medical devices industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Alphatec Holdings ATEC	10.4 M	$ 11.75	-3.29 %	$ 1.76 B	USA
BioSig Technologies BSGM	16 K	-	37.08 %	$ 85.7 M	USA
GenMark Diagnostics, Inc. GNMK	508 K	-	-	$ 1.77 B	USA
Delcath Systems DCTH	170 K	$ 8.98	-1.32 %	$ 322 M	USA
Aziyo Biologics AZYO	533 K	-	1.37 %	$ 20.5 M	USA
Acutus Medical AFIB	401 K	-	-26.83 %	$ 2.62 M	USA
Allied Healthcare Products AHPI	563 K	-	3.58 %	$ 2.21 M	USA
Obalon Therapeutics, Inc. OBLN	424 K	-	-5.86 %	$ 30.6 M	USA
Second Sight Medical Products EYES	335 K	-	-0.97 %	$ 54.4 M	USA
FONAR Corporation FONR	4.29 M	$ 18.41	0.38 %	$ 121 M	USA
Conformis CFMS	215 K	-	-	$ 16.4 M	USA
Cardiovascular Systems CSII	2.11 M	-	0.15 %	$ 844 M	USA
Inogen INGN	5.48 M	$ 6.32	-2.02 %	$ 168 M	USA
Apollo Endosurgery APEN	88 K	-	-	$ 475 M	USA
IRIDEX Corporation IRIX	2.4 M	$ 1.35	-	$ 21.8 M	USA
IRadimed Corporation IRMD	2.87 M	$ 100.97	1.78 %	$ 1.28 B	USA
CryoLife, Inc. CRY	1.45 M	-	-4.14 %	$ 702 M	USA
LivaNova PLC LIVN	11.5 M	$ 62.4	-1.33 %	$ 3.4 B	Britain
LENSAR LNSR	1.68 M	$ 5.56	-8.4 %	$ 64 M	USA
AxoGen AXGN	14 K	$ 32.61	2.71 %	$ 1.5 B	USA
Medtronic PLC MDT	315 M	$ 86.58	-0.68 %	$ 111 B	USA
Hancock Jaffe Laboratories, Inc. HJLI	33	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	732 K	-	0.03 %	$ 1.58 B	Israel
NanoVibronix NAOV	199	-	-	$ 1.08 M	USA
Misonix, Inc. MSON	13.3 K	-	-	$ 462 M	USA
InspireMD NSPR	20 K	$ 1.79	3.47 %	$ 115 M	Israel
Intersect ENT, Inc. XENT	137 K	-	-	$ 955 M	USA
Cytosorbents Corporation CTSO	419 K	$ 0.7	3.3 %	$ 38.1 M	USA
Aethlon Medical AEMD	345 K	$ 2.16	-6.09 %	$ 3.37 M	USA
Profound Medical Corp. PROF	358 K	$ 5.15	-4.63 %	$ 180 M	Canada
BIOLASE BIOL	2.45 M	-	-13.19 %	$ 166 K	USA
Penumbra PEN	9.16 M	$ 334.17	-0.41 %	$ 13 B	USA
AdaptHealth Corp. AHCO	59.8 M	$ 11.48	10.7 %	$ 1.55 B	USA
Myomo MYO	2.51 K	$ 0.7	-1.83 %	$ 29.3 M	USA
Nano-X Imaging Ltd. NNOX	140 K	$ 2.4	-1.64 %	$ 141 M	Israel
Invacare Corporation IVC	2.28 M	-	-	$ 24.7 M	USA
EDAP TMS S.A. EDAP	6.64 M	$ 3.91	4.83 %	$ 146 M	France
Quanterix Corporation QTRX	20.7 M	$ 3.82	-3.05 %	$ 163 M	USA
Outset Medical OM	13.8 M	$ 3.53	-2.35 %	$ 53.7 K	USA